ATE480524T1 - PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS - Google Patents
PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTSInfo
- Publication number
- ATE480524T1 ATE480524T1 AT06792493T AT06792493T ATE480524T1 AT E480524 T1 ATE480524 T1 AT E480524T1 AT 06792493 T AT06792493 T AT 06792493T AT 06792493 T AT06792493 T AT 06792493T AT E480524 T1 ATE480524 T1 AT E480524T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor agonists
- hormone receptor
- thyroid hormone
- pyridazinone derivatives
- pyridazinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70121505P | 2005-07-21 | 2005-07-21 | |
| PCT/EP2006/064093 WO2007009913A1 (en) | 2005-07-21 | 2006-07-11 | Pyridazinone derivatives as thyroid hormone receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480524T1 true ATE480524T1 (en) | 2010-09-15 |
Family
ID=37114368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06792493T ATE480524T1 (en) | 2005-07-21 | 2006-07-11 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US7452882B2 (en) |
| EP (1) | EP1919878B1 (en) |
| JP (1) | JP5000649B2 (en) |
| KR (1) | KR100965006B1 (en) |
| CN (1) | CN101228135B (en) |
| AR (1) | AR054848A1 (en) |
| AT (1) | ATE480524T1 (en) |
| AU (1) | AU2006271721C1 (en) |
| BR (1) | BRPI0613754B8 (en) |
| CA (1) | CA2614529C (en) |
| CR (1) | CR9644A (en) |
| CY (1) | CY1110929T1 (en) |
| DE (1) | DE602006016821D1 (en) |
| DK (1) | DK1919878T3 (en) |
| EC (1) | ECSP088120A (en) |
| ES (1) | ES2349131T3 (en) |
| HK (1) | HK1115129A1 (en) |
| HR (1) | HRP20100633T1 (en) |
| IL (1) | IL188476A (en) |
| MA (1) | MA29731B1 (en) |
| MX (1) | MX2008000818A (en) |
| MY (1) | MY142861A (en) |
| NO (1) | NO340679B1 (en) |
| NZ (1) | NZ565190A (en) |
| PL (1) | PL1919878T3 (en) |
| PT (1) | PT1919878E (en) |
| RS (1) | RS51639B (en) |
| RU (1) | RU2379295C2 (en) |
| TW (1) | TWI330636B (en) |
| UA (1) | UA88104C2 (en) |
| WO (1) | WO2007009913A1 (en) |
| ZA (1) | ZA200800405B (en) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| MX2007014502A (en) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Thyromimetics for the treatment of fatty liver diseases. |
| DE602006016821D1 (en) | 2005-07-21 | 2010-10-21 | Hoffmann La Roche | PYRIDAZINE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| WO2008133141A1 (en) * | 2007-04-24 | 2008-11-06 | Toyo Boseki Kabushiki Kaisha | Osmotin recombinant protein, method for production of the same, and use of the same |
| WO2008149379A2 (en) | 2007-06-06 | 2008-12-11 | Torrent Pharmaceuticals Ltd. | Novel compounds |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2524787T3 (en) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Pyridazinone derivatives as PARP inhibitors |
| KR100981781B1 (en) | 2008-02-29 | 2010-09-10 | 재단법인 한국원자력의학원 | Collimator device for radiotherapy and curing device using thereof |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| TWI534144B (en) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | Novel thyroid hormone β receptor agonist |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| JP5847533B2 (en) * | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | Novel thyroid hormone beta receptor agonist |
| EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (en) | 2011-03-08 | 2015-04-22 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| CN108101851A (en) * | 2012-09-17 | 2018-06-01 | 马德里加尔制药公司 | The method of synthetic thyroid hormone analogs and its polymorph |
| CN105272927A (en) * | 2015-11-17 | 2016-01-27 | 华中药业股份有限公司 | Novel method for preparing chlordiazepoxide |
| AU2017346871B2 (en) | 2016-10-18 | 2023-08-03 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a THR-beta agonist |
| JP2020500199A (en) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | Methods of treating glycogen storage disease |
| WO2018226604A1 (en) | 2017-06-05 | 2018-12-13 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP3683306A4 (en) | 2017-09-14 | 2021-06-09 | Riken | Method for producing retinal tissues |
| JP7156722B2 (en) * | 2018-01-23 | 2022-10-19 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | substituted pyridazinone compounds |
| HRP20220715T1 (en) | 2018-04-16 | 2022-09-30 | Ioulia Tseti | A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone |
| CA3099752C (en) * | 2018-06-12 | 2023-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
| CN110627773B (en) * | 2018-06-22 | 2021-03-19 | 海创药业股份有限公司 | Deuterated MGL-3196 compound and application thereof |
| AR115666A1 (en) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | SOLID FORMS OF 2- (3,5-DICHLORO-4 - ((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-IL) OXY) PHENYL) -3,5-DIOXO-2,3,4 , 5-TETRAHYDRO-1,2,4-TRIAZIN-6-CARBONITRILE |
| AU2019325656A1 (en) * | 2018-08-24 | 2021-03-11 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP3846821B1 (en) * | 2018-09-06 | 2023-10-04 | Galmed Research and Development Ltd. | Combination therapy for the treatment of liver disease |
| EP3864013A4 (en) * | 2018-10-12 | 2022-09-28 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| AU2019357618A1 (en) | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
| CN111592528A (en) * | 2019-02-20 | 2020-08-28 | 苏州泽璟生物制药股份有限公司 | Deuterated pyridazinone, derivatives thereof and pharmaceutical compositions |
| WO2020169069A1 (en) | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| WO2020184720A1 (en) | 2019-03-13 | 2020-09-17 | 大日本住友製薬株式会社 | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
| JP2022532706A (en) * | 2019-05-08 | 2022-07-19 | アリゴス セラピューティクス，インコーポレーテッド | THR-β regulator and its usage |
| CN111909137B (en) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | Pyridazinone derivative and application thereof |
| WO2020239076A1 (en) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | Pyridazinone derivatives as thyroxine receptor-β agonists and application thereof |
| WO2021032218A1 (en) | 2019-08-19 | 2021-02-25 | 苏州闻天医药科技有限公司 | HETEROCYCLIC THR-β RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR |
| CN112409340B (en) * | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | Halogen substituted phenyl ether compound and application thereof |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021043185A1 (en) * | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| AU2020346057A1 (en) * | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US20220411400A1 (en) * | 2019-09-24 | 2022-12-29 | Sunshine Lake Pharma Co., Ltd. | Chemical compound as thyroid hormone beta receptor agonist and use thereof |
| CN112707892A (en) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof |
| EP4083024A4 (en) * | 2019-11-26 | 2023-11-01 | KPC Pharmaceuticals, Inc. | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| CN114787153A (en) * | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | Resmetirom crystal form and preparation method and application thereof |
| CN113045551A (en) * | 2019-12-27 | 2021-06-29 | 广东东阳光药业有限公司 | Compound as thyroid hormone beta receptor agonist and application thereof |
| AU2021208027A1 (en) | 2020-01-13 | 2022-07-28 | Eccogene (Shanghai) Co., Ltd. | Substituted triazinones as thyroid hormone receptor agonists |
| CN113278013B (en) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof |
| CN113698388B (en) * | 2020-05-20 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 6-oxo-1, 6-dihydropyridine derivative, preparation method and application thereof in medicine |
| JP2023528637A (en) | 2020-06-02 | 2023-07-05 | 成都康弘▲葯▼▲業▼集▲團▼股▲フン▼有限公司 | Novel thyroid hormone beta receptor agonist |
| WO2022041026A1 (en) * | 2020-08-27 | 2022-03-03 | InventisBio Co., Ltd. | Pyridazinone compounds |
| JP2023541870A (en) * | 2020-09-10 | 2023-10-04 | ▲蘇▼州科睿思制▲葯▼有限公司 | Crystal form of RESMETIROM, its preparation method, and its use |
| WO2022053028A1 (en) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-triazine-3,5(2h,4h)-diketone compound and application thereof |
| CN116157512A (en) | 2020-09-11 | 2023-05-23 | 国立研究开发法人理化学研究所 | Composite comprising cell aggregate containing neural retina and matrix, and method for producing same |
| WO2022054924A1 (en) | 2020-09-11 | 2022-03-17 | 大日本住友製薬株式会社 | Medium for tissue for transplantation |
| WO2022068915A1 (en) * | 2020-09-30 | 2022-04-07 | 江苏恒瑞医药股份有限公司 | 6-oxo-1,6-dihydropyridazin derivative, preparation method therefor, and application thereof in medicine |
| EP4204419A1 (en) | 2020-10-19 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Solid state forms of resmetirom |
| US11858913B2 (en) | 2020-11-06 | 2024-01-02 | Aligos Therapeutics, Inc. | Bicyclic pyridazinones and methods of use thereof |
| CN112645936B (en) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | Substituted pyridazinone compound and use thereof |
| CN114685450A (en) | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-pyridone derivative, preparation method and medical application thereof |
| CN114907327A (en) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Crystal form of Resmetirom and preparation method and application thereof |
| CN115073429A (en) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | Salt form and crystal form of 1,2, 4-triazine-3, 5-diketone compound and preparation method thereof |
| CN115650928B (en) * | 2022-12-28 | 2023-03-31 | 凯思凯旭(上海)医药科技有限公司 | Polycyclic thyroid hormone beta receptor agonist and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582842A (en) * | 1981-02-25 | 1986-04-15 | Merck & Co., Inc. | Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor |
| GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| AU4440596A (en) | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of hcp SH2 specific compounds to enhance erythropoiesis |
| WO1996039388A1 (en) | 1995-06-06 | 1996-12-12 | Pfizer Inc. | Process for converting 2,4-dichloropyridines into 2-aryloxy-4-chloropyridines |
| CA2225668A1 (en) | 1995-06-30 | 1997-01-23 | Damien John Dunnington | Use of stat 6 sh2 domain specific compounds to treat allergic reactions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| AR023659A1 (en) | 1998-09-18 | 2002-09-04 | Vertex Pharma | AN INHIBITOR COMPOUND OF P38, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOSITION IN THE TREATMENT AND PREVENTION OF PATHOLOGICAL STATES |
| ID29889A (en) * | 1999-03-01 | 2001-10-18 | Pfizer Prod Inc | OXAMIC ACIDS AND ITS SUBSIDIARIES AS THIROID LIGHTS RECEPTORS |
| WO2002051805A1 (en) * | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indole derivatives as ligands of thyroid receptors |
| CA2435820A1 (en) * | 2001-02-08 | 2002-08-15 | Karo Bio Ab | Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
| EP1236720B1 (en) * | 2001-02-28 | 2005-06-15 | Pfizer Products Inc. | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| CA2559552A1 (en) * | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors |
| DE602006016821D1 (en) | 2005-07-21 | 2010-10-21 | Hoffmann La Roche | PYRIDAZINE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS |
-
2006
- 2006-07-11 DE DE602006016821T patent/DE602006016821D1/en active Active
- 2006-07-11 JP JP2008521935A patent/JP5000649B2/en active Active
- 2006-07-11 ES ES06792493T patent/ES2349131T3/en active Active
- 2006-07-11 MX MX2008000818A patent/MX2008000818A/en active IP Right Grant
- 2006-07-11 CA CA2614529A patent/CA2614529C/en active Active
- 2006-07-11 AT AT06792493T patent/ATE480524T1/en active
- 2006-07-11 RS RS20100527A patent/RS51639B/en unknown
- 2006-07-11 PT PT06792493T patent/PT1919878E/en unknown
- 2006-07-11 DK DK06792493.6T patent/DK1919878T3/en active
- 2006-07-11 AU AU2006271721A patent/AU2006271721C1/en active Active
- 2006-07-11 RU RU2008106058/04A patent/RU2379295C2/en active
- 2006-07-11 PL PL06792493T patent/PL1919878T3/en unknown
- 2006-07-11 NZ NZ565190A patent/NZ565190A/en unknown
- 2006-07-11 EP EP06792493A patent/EP1919878B1/en active Active
- 2006-07-11 WO PCT/EP2006/064093 patent/WO2007009913A1/en active Application Filing
- 2006-07-11 BR BRPI0613754A patent/BRPI0613754B8/en active IP Right Grant
- 2006-07-11 KR KR1020087001480A patent/KR100965006B1/en active IP Right Grant
- 2006-07-11 CN CN2006800267317A patent/CN101228135B/en active Active
- 2006-07-18 TW TW095126242A patent/TWI330636B/en active
- 2006-07-18 US US11/488,870 patent/US7452882B2/en active Active
- 2006-07-19 MY MYPI20063456A patent/MY142861A/en unknown
- 2006-07-19 AR ARP060103084A patent/AR054848A1/en active IP Right Grant
- 2006-11-07 UA UAA200801933A patent/UA88104C2/en unknown
-
2007
- 2007-12-27 IL IL188476A patent/IL188476A/en active IP Right Grant
-
2008
- 2008-01-04 NO NO20080058A patent/NO340679B1/en unknown
- 2008-01-08 CR CR9644A patent/CR9644A/en unknown
- 2008-01-14 ZA ZA2008/00405A patent/ZA200800405B/en unknown
- 2008-01-18 EC EC2008008120A patent/ECSP088120A/en unknown
- 2008-02-01 MA MA30618A patent/MA29731B1/en unknown
- 2008-08-20 US US12/194,643 patent/US7807674B2/en active Active
- 2008-09-17 HK HK08110278.4A patent/HK1115129A1/en unknown
-
2010
- 2010-11-22 CY CY20101101049T patent/CY1110929T1/en unknown
- 2010-11-23 HR HR20100633T patent/HRP20100633T1/en unknown
-
2015
- 2015-07-01 US US14/788,921 patent/USRE46024E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE480524T1 (en) | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | |
| ATE504559T1 (en) | ARYLANILINE DERIVATIVES AS BETA2-ADRENERGIC RECEPTOR AGONISTS | |
| DE602006003628D1 (en) | PURE DERIVATIVES AS A2A RECEPTOR AGONISTS | |
| ATE549350T1 (en) | NEUROPEPTIDE-2 RECEPTOR AGONISTS | |
| ATE502040T1 (en) | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | |
| ATE481404T1 (en) | ADENOSINE DERIVATIVES AS AGONISTS AT THE A2A RECEPTOR | |
| IL188550A0 (en) | Heterocyclic compounds as agonists for the thyroid receptor | |
| ATE513827T1 (en) | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | |
| ATE420088T1 (en) | QUINOLINONECARBONIC ACID AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | |
| ATE509927T1 (en) | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | |
| DE602006015607D1 (en) | THIAZOL-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | |
| NL1028624A1 (en) | Alpha-aryl or heteroarylmethyl-beta-piperidinopropanoic acid compounds as ORL1 receptor antagonists. | |
| IS8842A (en) | Nuclear receptor binding agents. | |
| ATE478064T1 (en) | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | |
| ATE555111T1 (en) | QUINUCLIDINOL DERIVATIVES AS MUSCARINE RECEPTOR ANTAGONISTS | |
| DE602006020447D1 (en) | NIACIN RECEPTOR AGONISTS, COMPOSITIONS WITH DE | |
| DE602007010456D1 (en) | PHENYL-PYRAZOL DERIVATIVES AS NON-STEROID GLUCOCORTICOID RECEPTOR LIGANDS | |
| DK1973886T3 (en) | PROKINETICIN-1 Receptor Antagonists | |
| DK2081951T3 (en) | Progesterone receptor antagonists | |
| DE602005004404D1 (en) | AS HISTAMIN-3 RECEPTOR LIGANDS INSERTABLE NAPHTHALENE DERIVATIVES | |
| NL2000241A1 (en) | Carboxamide derivatives as muscarinic receptor antagonists. | |
| ATE535523T1 (en) | BENZIMIDAZOLECARBONIC ACID AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | |
| ATE477243T1 (en) | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | |
| ATE459618T1 (en) | 3-PIPERIDINYLISOCHROMANE-5-OLS AS DOPAMINE AGONISTS | |
| ATE534628T1 (en) | UROTENSIN II RECEPTOR ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1919878 Country of ref document: EP |